GEN Exclusives

More »

GEN News Highlights

More »
Mar 9, 2009

SARcode Pays $2M for Sunesis’ LFA-1 Inhibitor Program

  • SARcode bought Sunesis Pharmaceuticals' intellectual property and assets related to the LFA-1 inhibitor program for $2 million. The lead candidate, SAR 1118, which has yet to begin Phase I testing, is a small molecule LFA-1 inhibitor being developed for T-cell mediated ophthalmic diseases.

    SARcode previously had a license to this program. The license agreement will now be terminated, and Sunesis will forego future milestone payments and royalties.

    “Consistent with our strategy to focus our resources on advancing voreloxin, our novel investigational anticancer drug candidate currently being developed for acute myeloid leukemia and ovarian cancer, we made the decision to monetize our milestone and royalty rights in SARcode's LFA-1 program,” says Daniel Swisher, CEO of Sunesis. Voreloxin is in Phase II trials.

    “We have been impressed with the progress of SAR 1118 to date and retain an interest in the future success of this program through our convertible notes.” The convertible notes have a total principal value of $1 million.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »